fda warning letters compounded semaglutide tirzepatide 2025 🚨 Moves to Permanently Shut Down GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like and tirzepatide, signaling a major shift in how these FDA and Novo Nordisk Warned

The treatment did not initially affect body weight or food and water consumption

In June 2026, the agency sent its third wave of warning letters in about a year to telehealth companies marketing compounded semaglutide and tirzepatide, citing misleading claims and undisclosed compounding pharmacies

[Crossref] Vilsbll T, Bain SC, Leiter LA (2018) Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy

Mochi Health is a telehealth company based in San Francisco that connects patients with licensed providers for weight loss treatment, including compounded and brand-name GLP-1 medications like tirzepatide and semaglutide